Congress Should Open CBD Door, Close VMS Market Holes – Sharfstein, Cohen
Executive Summary
"We seem to be headed toward a confusing, uneven, and potentially risky market in CBD products. This situation creates an opportunity for Congress to take action," say Joshua Sharfstein and Pieter Cohen in NEJM. Additionally, GW Pharma exec says FDA should reign in the "unfettered" production and sales of food and supplements containing CBD , hemp or other cannabis-based ingredients to prevent potential harm to consumers.
You may also be interested in...
Sales Of Drug-Spiked Supplements After Warnings Show Stronger US Regulation Needed – Study
"FDA should consider ways to ensure that prohibited drugs are removed from supplements, perhaps by testing products sold after warning letters and mandating recalls whenever products remain adulterated,” say Pieter Cohen and colleagues in JAMA study.
Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish
Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.